| 摘要 |
Provided are uses of agents interfering with the interaction of TIRC7 with i ts ligand such as HLA-(Human Leukocyte associated Antigen) class II alpha (.alpha.) chain for the preparation of pharmaceutical compositions for the treatment of graft versus host disease, autoimmune diseases, allergic diseases, infectious diseases, sepsis, for the treatment of tumors, for the improvement of wound healing or for inducing or maintaining immune unresponsiveness in a subject. In addition, methods for identifying and obtaining such agents are described. Furthermore, methods of diagnosing an immune disease or a tumor by determining the presence or absence of TIRC7 ligand are provided.
|
